Introduction
============

Osteosarcoma is the most common primary bone tumor in children and adolescents, with traditional therapeutic protocols comprising chemotherapy and surgical resection \[[@b1-kjp-2018-06618]\]. Previous studies have suggested several clinical features related to prognosis, including age, tumor location and size, histologic response to chemotherapy, and serum alkaline phosphatase level \[[@b2-kjp-2018-06618]\]. Histologic response to preoperative chemotherapy is the most agreed-upon prognostic indicator; however, it can only be obtained after surgery \[[@b2-kjp-2018-06618]\]. Thus, a new clinical prognostic indicator available early in therapy is necessary.

Leukocyte count in the peripheral blood of cancer patients has prognostic significance. Reported clinical data have shown that a low lymphocyte count was associated with advanced stages and poor survival of cancer patients \[[@b3-kjp-2018-06618]\]. Recently it has been suggested that the lymphocyte-monocyte ratio (LMR) has prognostic significance in various cancers \[[@b4-kjp-2018-06618]\]. In patients with diffuse large Bcell and Hodgkin lymphoma, a low pretreatment LMR indicated a poor prognosis \[[@b5-kjp-2018-06618],[@b6-kjp-2018-06618]\]. Additionally, in patients with nonhematologic malignancies, including breast, colorectal, lung, and nasopharyngeal carcinomas, a low pretreatment LMR represented an unfavorable prognosis \[[@b7-kjp-2018-06618]-[@b10-kjp-2018-06618]\]. In pediatric malignancies, limited data are available about the prognostic significance of lymphocyte counts or the LMR. Furthermore, previous studies varied in the time point of analysis (pretreatment or at the nadir of first chemotherapy) or leukocyte indices (LMR or lymphocyte count). It has been reported that the absolute lymphocyte count (ALC) at the end of induction chemotherapy is a prognostic factor in childhood acute lymphoblastic leukemia \[[@b11-kjp-2018-06618]-[@b13-kjp-2018-06618]\]. Preoperative LMR was a predictor of survival in patients with osteosarcoma \[[@b14-kjp-2018-06618]\]. Early lymphocyte recovery after first chemotherapy, defined at day 14 or 15, was associated with better outcomes in children with osteosarcoma and Ewing sarcoma \[[@b15-kjp-2018-06618]-[@b17-kjp-2018-06618]\].

In this retrospective study, we analyzed leukocyte counts and their ratios in the peripheral blood of pediatric patients with osteosarcoma and evaluated their association with treatment outcomes. Most previous studies analyzed the prognostic value of pretreatment lymphocyte counts and LMR. Day 14 of cytotoxic chemotherapy is usually considered as the nadir, and we hypothesized that the leukocyte count and its ratios at this time point might reflect the actual immune status against the tumor. Leukocyte counts and ratios at 2-time points (pretreatment and day 14) were assessed, and we found that day 14 LMR (LMR14), as well as pretreatment lymphocyte count, had prognostic significance in pediatric osteosarcoma patients.

Materials and methods
=====================

1. Patients and treatments
--------------------------

We retrospectively identified 27 patients with osteosarcoma, treated at the Pediatric Department of Korea Cancer Center Hospital between May 2002 and March 2016. The study was approved by The Institutional Review Board of Korea Cancer Center Hospital (K-1710-002-014). Patients met the following criteria; (1) high-grade primary osteosarcoma; (2) no evidence of distant metastasis, i.e., localized disease; (3) no history of previous treatment, and (4) complete blood cell counts were tested before treatment and at the 14th day of first cisplatin-doxorubicin chemotherapy at our institution. Seven cases underwent surgery first and subsequently received 6 courses of combination chemotherapy. The remaining 20 patients received 2 courses of preoperative chemotherapy before undergoing definitive surgery. The standard chemotherapy was comprised of high-dose methotrexate (12 g/m^2^ on days 1 and 8), cisplatin (100 mg/m^2^ on day 15), and doxorubicin (60 mg/m^2^ over 48 hours, on day 15). Postoperative chemotherapy was modified according to the histologic response; 8 patients with a good response (≤10% residual viable tumor) \[[@b18-kjp-2018-06618]\] received the same therapy as the preoperative chemotherapy, while 12 cases with poor response (\>10% residual viable tumor) \[[@b18-kjp-2018-06618]\] were switched to an ifosfamidebleomycin-doxorubicin-cisplatin based protocol. The dosages of cisplatin and doxorubicin were the same as the preoperative doses, and ifosfamide (14 g/m^2^) was infused continuously with bleomycin (30 mg/m^2^) for 7 days.

2. Statistical analysis
-----------------------

Patients were dichotomized according to the median values of absolute neutrophil count (ANC), ALC, absolute monocyte count (AMC), and LMR measured before treatment and at day 14 of first cisplatin-doxorubicin chemotherapy. Survival analysis was performed using the Kaplan-Meier method, and survival differences between the 2 groups were evaluated using the log-rank test. All calculations were performed using SPSS ver. 11.5 (SPSS Inc., Chicago, IL, USA), and *P* values of \<0.05 were considered significant.

Results
=======

The median age of the 27 patients (9 female and 18 male) was 9.9 years (range, 3.2--14.1 years). The tumor sites were distal femur (n=14), proximal humerus (n=7), proximal tibia (n=2), proximal fibula (n=2), and elsewhere (n=2) ([Table 1](#t1-kjp-2018-06618){ref-type="table"}). All patients received granulocyte colony stimulating factor during the neutropenic period after chemotherapy, starting from a neutrophil count \<500/μL. In addition to selected 5-hydroxytryptamine receptor antagonists, dexamethasone was used as an antiemetic for all patients when they received cisplatin and doxorubicin. The median pretreatment ANC, ALC, and AMC were 3,610/μL (range, 1,510--11,020/μL), 2,320/μL (range, 1,430--4,590/μL), and 370/μL (range, 200--1,011/μL), respectively. The median pretreatment LMR was 6.3 (range, 2.3--21.5). At day 14 of first cisplatin-doxorubicin chemotherapy, median values of ANC, ALC, and AMC were 580/μL (range, 40--5,470/μL), 1,540/μL (range, 650--2,610/μL), and 300/μL (range, 70--890/μL), respectively. In addition, the median LMR14 was 5.0 (range, 1.8--24.9).

Patients were followed for a median of 76.4 months (range, 4.5--174.7 months) and the 5-year overall (OS) and event-free survival (EFS) rates were 66.0%±9.8% and 60.9%±9.7%, respectively. The 7 patients who underwent surgery first had similar OS and EFS to those who received surgery after chemotherapy. The 5-year OS and EFS were not different according to age and tumor location. For the 20 patients who received preoperative chemotherapy, histologic response tended to affect EFS (*P*=0.09) ([Table 2](#t2-kjp-2018-06618){ref-type="table"}).

Patients were dichotomized according to the median values of pretreatment and day 14 ANC, ALC, AMC, and LMR, and survival rates were compared ([Table 2](#t2-kjp-2018-06618){ref-type="table"}). Patients with a higher pretreatment ALC had a better OS and EFS ([Fig. 1A](#f1-kjp-2018-06618){ref-type="fig"}). However, survival was not different between the 2 patient groups according to their ALC values at day 14. We observed that a higher LMR14 was associated with a favorable outcome in osteosarcoma patients, while pretreatment LMR had no impact. Patients with an LMR14 ≥5.0 had a better OS than those with a lower LMR14 (\<5.0) (*P*=0.04) ([Fig. 1B](#f1-kjp-2018-06618){ref-type="fig"}). EFS also tended to be better in patients with an LMR14 ≥5.0 than in those with an LMR14 \<5.0 (*P*=0.06) ([Fig. 1B](#f1-kjp-2018-06618){ref-type="fig"}).

Discussion
==========

The role of the immune system has been demonstrated in many cancers. A low lymphocyte count has been observed in patients with advanced stages of cancer and is associated with poor survival \[[@b3-kjp-2018-06618]\]. Early lymphocyte recovery during chemotherapy has been associated with a better prognosis \[[@b11-kjp-2018-06618]-[@b13-kjp-2018-06618],[@b15-kjp-2018-06618]-[@b17-kjp-2018-06618]\]. In the present study, we observed that a higher pretreatment lymphocyte count was associated with favorable prognosis of pediatric osteosarcoma, while the day 14 lymphocyte count was not. Interestingly, the LMR14 was associated with better survival of pediatric patients with osteosarcoma.

There are some limitations in our study. First, this was a retrospective study involving a small number of patients and treatments were not homogeneous, with 7 cases receiving surgery before chemotherapy. However, the survival rates of the 7 patients were similar to those who received chemotherapy before surgery, and we assumed that treatment heterogeneity had little impact on our study. Second, we analyzed the leukocyte count of the peripheral blood as a surrogate for the patients' immune systems. Lymphocyte or monocyte infiltrates in the osteosarcoma tissue would more accurately reflect the anti-tumor immune response. However, this evaluation was not possible due to a limited amount of the biopsy samples; instead, we presumed that peripheral leukocyte count might correlate with lymphocyte or monocyte infiltrates in the osteosarcoma tissue.

It is unclear why osteosarcoma patients with a higher LMR had a better outcome. We surmised that LMR in peripheral blood may be surrogate of tumor-infiltrating immune cell populations and reflect a balance between immune effector cells (lymphocytes) and the tumor microenvironment (monocytes). Many studies demonstrated that lymphocyte counts in peripheral blood and the presence of tumor-infiltrating lymphocytes (TIL) are associated with favorable prognosis in patients with melanoma, lung, kidney, breast and ovarian cancer \[[@b19-kjp-2018-06618]-[@b21-kjp-2018-06618]\]. Meanwhile, it is suggested that lymphocyte counts in peripheral blood are prognostic due to an association with disease burden rather than TILs \[[@b22-kjp-2018-06618]\]. In contrast, monocytes or macrophages could promote tumor progression \[[@b23-kjp-2018-06618]-[@b26-kjp-2018-06618]\]. Increased numbers of monocytes in tumor tissues (tumor-associated macrophages, TAMs) were associated with the reduced survival of cancer patients \[[@b25-kjp-2018-06618],[@b26-kjp-2018-06618]\]. TAMs are derived from monocytes in the peripheral blood and secrete cytokines, suppress the immune response, and promote angiogenesis \[[@b26-kjp-2018-06618]\]. It has been suggested that some monocytes in the peripheral blood may be myeloid-derived suppressor cells (MDSC) \[[@b27-kjp-2018-06618]\]. Elevated numbers of MDSCs in the peripheral blood were associated with shorter survival in patients with nonsmall cell lung cancer, colorectal, bladder, and thyroid cancers \[[@b27-kjp-2018-06618]\]. Recent studies have demonstrated that a high MDSC number are correlated with a poor response to ipilimumab or nivolumab \[[@b28-kjp-2018-06618],[@b29-kjp-2018-06618]\]. We surmised that LMR in peripheral blood may be surrogate of tumor-infiltrating immune cell populations and reflect a balance between immune effector cells (lymphocytes) and the tumor microenvironment (monocytes). As the exact relationship between 2 compartments (peripheral blood and tumor microenvironment) is poorly understood, further studies are necessary.

While the prognostic significance of pretreatment LMR has been reported for several cancers \[[@b4-kjp-2018-06618]-[@b9-kjp-2018-06618],[@b10-kjp-2018-06618],[@b13-kjp-2018-06618]\], little data exist about the postchemotherapy LMR. In patients with diffuse large B-cell lymphoma, a low peripheral blood ALC/AMC ratio during R- CHOP cycle predicted inferior outcome \[[@b30-kjp-2018-06618]\]. In patients with acute lymphoblastic leukemia \[[@b11-kjp-2018-06618],[@b12-kjp-2018-06618]\], non-Hodgkin lymphoma \[[@b13-kjp-2018-06618]\], Ewing sarcoma \[[@b17-kjp-2018-06618]\], and osteosarcoma \[[@b15-kjp-2018-06618],[@b16-kjp-2018-06618]\], early lymphocyte recovery after chemotherapy is associated with a better outcome. Lymphopenia or late recovery during chemotherapy may be the result of preexisting immune dysfunction and/or T-lymphocyte inhibiting cytokines produced by the tumor cells \[[@b22-kjp-2018-06618]\]. We consider that a high LMR following chemotherapy suggests a dominant antitumor immune response of the lymphocytes.

In conclusion, a higher pretreatment lymphocyte count at diagnosis was associated with favorable prognosis of pediatric osteosarcoma, while the day 14 lymphocyte count was not. Furthermore, LMR14 after the first cisplatin-doxorubicin chemotherapy was associated with an improved outcome in pediatric patients with osteosarcoma. These indices may be used as prognostic indicators and potentially as biomarkers to predict the clinical response to immunotherapy in patients with osteosarcoma. As limited data exist about the prognostic significance of postchemotherapy LMR, further studies involving larger cohorts are necessary to validate our findings.
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![(A) Patients with a higher pretreatment absolute lymphocyte count (ALC) had better overall survival (OS) and eventfree survival (EFS). (B) Patients with a higher lymphocyte-monocyte ratio on day 14 of chemotherapy (LMR14) had better OS and a tendency for better EFS.](kjp-2018-06618f1){#f1-kjp-2018-06618}

###### 

Clinical characteristics of the 27 patients with osteosarcoma

  Case   Age (yr)/sex   Location            Pretreatment   At day14 of cisplatin-doxorubicin   Events (mo)   Follow-up (mo)   Final status                                                     
  ------ -------------- ------------------- -------------- ----------------------------------- ------------- ---------------- -------------- ------- ----- ------ -------------------- ------- -----
  1      7.8/M          Fibula              3,660          1,810                               350           10.5             970            850     360   2.7    \-                   118.7   CDF
  2      10.2/M         Femur, distal       1,960          2,910                               280           7.0              1,420          580     70    20.3   Lung meta (11.5)     47.7    DOD
  3      9.7/F          Femur, distal       4,300          2,800                               200           21.5             2,030          4610    820   2.5    \-                   110.2   CDF
  4      3.2/M          Humerus, proximal   2,470          2,890                               330           7.5              1,560          40      140   11.1   \-                   32.4    CDF
  5      9.1/M          Femur, distal       1,790          5,660                               430           4.2              1,750          2,060   260   6.7    \-                   72.8    CDF
  6      12.5/M         Humerus, proximal   1,730          3,020                               370           4.7              1,330          210     90    14.8   Lung meta (6.9)      174.7   NED
  7      5.0/M          Humerus, proximal   1,980          6,020                               340           5.8              2,010          600     400   5.0    Lung meta (26.8)     37.5    DOD
  8      8.8/M          Femur, distal       1,850          3,590                               470           3.9              1,500          250     90    16.7   \-                   123.4   CDF
  9      14.1/M         Femur, distal       1,910          6,080                               820           2.3              1,410          130     70    20.1   \-                   126.9   CDF
  10     4.8/M          Femur, distal       4,590          7,040                               910           5.0              2,340          140     340   6.9    \-                   11.0    CDF
  11     7.8/F          Humerus, proximal   2,520          3,610                               270           9.3              2,600          2,540   890   2.9    \-                   88.3    CDF
  12     6.6/F          Radius, distal      3,330          3,520                               430           7.7              880            70      200   4.4    \-                   122.2   CDF
  13     10.9/F         Humerus, proximal   2,010          5,680                               320           6.3              650            240     260   2.5    Lung meta (25.5)     53.9    DOD
  14     11.6/M         Femur, distal       1,770          5,770                               420           4.2              830            1,470   280   3.0    Local recur (16.1)   56.1    DOD
  15     10.3/F         Femur, distal       2,320          4,870                               220           10.5             2,550          1,210   770   3.3    \-                   34.7    CDF
  16     9.9/M          Femur, distal       1,430          4,120                               400           3.6              1,020          500     170   6.0    \-                   163.2   CDF
  17     9.0/M          Tibia, proximal     2,600          4,780                               300           8.7              2,610          260     320   8.2    \-                   112.0   CDF
  18     12.4/M         Humerus, proximal   2,890          3,270                               380           7.6              2,560          320     580   4.4    lung meta (13.6)     69.6    DOD
  19     9.0/F          Femur, distal       2,780          8,800                               390           7.1              1,320          830     180   7.3    \-                   76.4    CDF
  20     11.1/M         Femur, distal       2,100          4,650                               420           5.0              1,740          1,810   70    24.9   \-                   163.3   CDF
  21     10.8/F         Tibia, distal       2,690          3,350                               230           11.7             1,500          100     300   5.0    \-                   150.9   CDF
  22     12.2/F         Femur, distal       1,660          11,020                              550           3.0              1,030          4,360   400   2.6    Lung meta (25.6)     38.5    DOD
  23     10.4/M         Tibia, proximal     2,422          4,920                               1,011         2.4              2,230          100     100   22.3   \-                   110.0   CDF
  24     4.8/M          Fibula shaft        1,560          1,510                               250           6.2              1,540          5,470   850   1.8    Infection (4.5)      4.5     TRM
  25     11.8/F         Femur, distal       3,050          3,480                               320           9.5              1,610          2,710   530   3.0    Lung meta (18.6)     127.1   DOD
  26     13.7/M         Humerus, proximal   1,470          2,670                               530           2.8              930            370     420   2.2    bone meta (9.1)      11.3    DOD
  27     5.6/M          Femur, distal       2,640          3,070                               280           9.4              1,820          300     350   5.2    \-                   15.1    CDF

ALC14, absolute lymphocyte count at day14; ANC14, absolute neutrophil count at day 14; AMC14, absolute monocyte count at day14; LMR, lymphocyte-monocyte ratio; meta, metastasis; CDF, continuously disease-free; DOD, died of disease; NED, no evidence of disease; TRM, treatment-related mortality.

###### 

Five-year survival according to clinical variables including leukocyte counts

  Variable                                                               No. of cases   OS (%)      *P* value   EFS (%)     *P* value
  ---------------------------------------------------------------------- -------------- ----------- ----------- ----------- -----------
  Sex                                                                                               0.80                    0.52
   Male                                                                  18             61.3±12.5               58.4±12.2   
   Female                                                                9              75.0±15.3               66.7±15.7   
  Tumor location                                                                                    0.37                    0.17
   Distal femur                                                          14             72.7±13.4               67.1±13.5   
   Proximal tibia                                                        2              100                     100         
   Proximal humerus                                                      7              34.3±19.5               28.6±17.1   
   Elsewhere                                                             4              75.0±21.7               75.0±21.7   
  Neoadjuvant chemotherapy                                                                          0.50                    0.19
   Yes                                                                   20             63.3±11.0               53.1±11.4   
   No                                                                    7              75.0±21.7               83.3±15.2   
  Histologic response^[\*](#tfn1-kjp-2018-06618){ref-type="table-fn"}^                              0.11                    0.09
   Good                                                                  7              83.3±15.2               83.3±15.2   
   Poor                                                                  13             53.9±13.8               38.5±13.5   
  Leukocyte counts                                                                                                          
   Pretreatment                                                                                                             
   ALC                                                                                                                      
    ≥2,320/µL                                                            14             90.0±9.5    0.04        83.9±10.5   0.02
    \<2,320/µL                                                           13             46.2±13.8               38.5±13.5   
   AMC                                                                                              0.57                    0.97
    ≥370/µL                                                              14             69.2±12.8               62.3±13.4   
    \<370/µL                                                             13             51.3±15.8               59.2±14.1   
   ANC                                                                                              0.63                    0.20
    \<3,610/µL                                                           13             65.8±14.1               52.8±14.1   
    ≥3,610/µL                                                            14             66.7±13.6               69.2±12.8   
   ALC/AMC                                                                                          0.21                    0.16
    ≥6.3                                                                 13             80.0±12.7               76.2±12.1   
    \<6.3                                                                14             54.2±13.8               47.1±13.8   
  At day 14 of CDDP-ADR                                                                                                     
   ALC                                                                                              0.77                    0.44
    \<1,540/µL                                                           13             61.5±13.5               53.9±13.8   
    ≥1,540/µL                                                            14             72.2±13.9               68.1±13.3   
   AMC                                                                                              0.25                    0.44
    \<300/µL                                                             13             75.0±12.5               69.2±12.8   
    ≥300/µL                                                              14             56.8±14.9               52.0±14.4   
   ANC                                                                                              0.19                    0.27
    \<580/µL                                                             13             81.5±11.9               75.2±12.6   
    ≥580/ µL                                                             14             54.2±13.8               50.0±13.4   
   ALC/AMC (LMR14)                                                                                  0.04                    0.06
    \<5.0                                                                12             46.3±15.0               41.7±14.2   
    ≥5.0                                                                 15             83.3±10.8               78.3±11.2   

Values are presented as mean±standard deviation.

OS, overall survival; EFS, event-free survival; CDDP-ADR, cisplatin-adriamycin; ALC, absolute lymphocyte count; AMC, absolute monocyte count; ANC, absolute neutrophil count; LMR, lymphocyte-monocyte ratio.

Analyzed in 20 patients who received preoperative chemotherapy.
